For the study, the researchers analyzed 1,300 prostate tumor samples and found that, on average, those from Black men had higher levels of plasma cells (a type of immune cell) than those from white men.
E-Mail
IMAGE: MRI image of a patient s shoulder. The red arrow points to inflammation in the joint. The COVID virus triggered rheumatoid arthritis in this patient with prolonged shoulder pain after other. view more
Credit: Northwestern University
CHICAGO - Muscle soreness and achy joints are common symptoms among COVID-19 patients. But for some people, symptoms are more severe, long lasting and even bizarre, including rheumatoid arthritis flares, autoimmune myositis or COVID toes.
A new Northwestern Medicine study has, for the first time, confirmed and illustrated the causes of these symptoms through radiological imaging. We ve realized that the COVID virus can trigger the body to attack itself in different ways, which may lead to rheumatological issues that require lifelong management, said corresponding author Dr. Swati Deshmukh.
A drug marketed for Type 2 diabetes could change the way we treat obesity in the future.
Feb 17th, 2021
I know the headline sounds like bad clickbait, but there’s an anti-obesity medication that’s disrupting the industry. According to a recent article from
The New York Times, the drug is so effective that obese patients who take it could also prevent other consequences such as diabetes. The drug is semaglutide from Novo Nordisk, and it’s already marketed as a treatment for Type 2 diabetes.
In a clinical trial, subjects who injected it weekly for 68 weeks lost almost 15% of their body weight, compared to just 2.4% in the placebo group. Over a third of patients who received semaglutide lost more than 20% of their body weight, and many patients experienced improved symptoms of diabetes and pre-diabetes. Dr. Robert F. Kushner, an obesity researcher at Northwestern University Feinberg School of Medicine and leader of the study said, “The drug is a game-changer. This is the s